AstraZeneca Q3 Preview: Oncology Portfolio Keeps Growing

Sales of Lynparza, Tagrissa And Imfinzi Stay Strong

AstraZeneca, which analysts said had an 'exceptional' second quarter, is expected to have also kept that momentum up in the third quarter.

AstraZeneca_Phone
AstraZeneca reports third-quarter results 24 October • Source: Shutterstock

When AstraZeneca PLC delivers its third quarter financials on 24 October, investors will be expecting another strong performance and hoping for positive updates on its promising pipeline as well as three oncology drugs deemed particularly vital to the UK firm's future, those being Lynparza (olaparib), Tagrisso (osimertinib) and Imfinzi (durvalumab).

Also awaited will be updates on AstraZeneca’s mid- and late-stage pipeline, and news on potential additional indications for existing therapies.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.